REFERENCES
1. Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian Asian men. PLoS One 2011;5:e11961.
2. Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011;60:1329-39.
3. Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, et al. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet 2012;5:242-9.
4. Avery CL, He Q, North KE. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet 2011;7:e1002322.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. european group for the study of insulin resistance (EGIR). Diabet Med 1999;16:442-3.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
8. Grundy SM, Brewer HB, Cleeman JI, Smith SC Jr, Lenfant C, et al. Definition of metabolic syndrome: report of the National, Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
9. Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640-5.
11. Rankinen T, Sarzynski MA, Ghosh S, Bouchard C. Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors? Circ Res 2015;116:909-22.
12. Sazonova M, Budnikov E, Khasanova Z, Sobenin I, Postnov A, et al. Studies of the human aortic intima by a direct quantitative assay of mutant alleles in the mitochondrial genome. Atherosclerosis 2009;204:184-90.
13. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Mitochondrial mutations are associated with atherosclerotic lesions in the human aorta. Clin Dev Immunol 2012;2012:832464.
14. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease. Atherosclerosis 2013;227:283-8.
15. Sazonova MA, Sinyov VV, Barinova VA, Ryzhkova AI, Zhelankin AV, et al. Mosaicism of mitochondrial genetic variation in atherosclerotic lesions of the human aorta. Biomed Res Int 2015;2015:825468.
16. Sobenin IA, Sazonova MA, Ivanova MM, Zhelankin AV, Myasoedova VA, et al. Mutation C3256T of mitochondrial genome in white blood cells: novel genetic marker of atherosclerosis and coronary heart disease. PLoS One 2012;7:e46573.
17. Sobenin IA, Sazonova MA, Postnov AY, Salonen JT, Bobryshev YV, et al. Association of mitochondrial genetic variation with carotid atherosclerosis. PLoS One 2013;8:e68070.
18. Sazonova MA, Chicheva MM, Zhelankin AV, Sobenin IA, Bobryshev YV, et al. Association of mutations in the mitochondrial genome with the subclinical carotid atherosclerosis in women. Exp Mol Pathol 2015;99:25-32.
19. Sinyov VV, Sazonova MA, Ryzhkova AI, Galitsyna EV, Melnichenko AA, et al. Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations. Vessel Plus 2017;1:145-50.
20. Sazonova MA, Ryzhkova AI, Sinyov VV, Galitsyna EV, Orekhova VA, et al. New markers of atherosclerosis: a threshold level of heteroplasmy in mtDNA mutations. Vessel Plus 2017;1:182-91.
21. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-64.
22. Sobenin IA, Surnin SA, Karagodin VP, Miasoedova VA, Kirichenko TV, et al. Variability of intima-media thickness of the common carotid arteries in Moscow city population without clinical symptoms of atherosclerosis. Ter Arkh 2011;83:58-62.
23. Mitchell AL, Elson JL, Howell N, Taylor RW, Turnbull DM. Sequence variation in mitochondrial complex I genes: mutation or polymorphism? J Med Genet 2006;43:175-9.
24. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007;83:84-92.
25. Springer MS, Douzery E. Secondary structure and patterns of evolution among mammalian mitochondrial 12S rRNA molecules. J Mol Evol 1996;43:357-73.
26. Shen SS, Liu C, Xu ZY, Hu YH, Gao GF, et al. Heteroplasmy levels of mtDNA1555A>G mutation is positively associated with diverse phenotypes and mutation transmission in a Chinese family. Biochem Biophys Res Commun 2012;420:907-12.
27. Ealy M, Lynch KA, Meyer NC, Smith RJ. The prevalence of mitochondrial mutations associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. Laryngoscope 2011;121:1184-6.
28. Rossmanith W, Karwan RM. Impairment of tRNA processing by point mutations in mitochondrial tRNA(Leu) (UUR) associated with mitochondrial diseases. FEBS Lett 1998;433:269-74.
29. Krag TO, Hauerslev S, Jeppesen TD, Duno M, Vissing J. Muscle regeneration in mitochondrial myopathies. Mitochondrion 2013;13:63-70.
30. Valente L, Piga D, Lamantea E, Carrara F, Uziel G, et al. Identification of novel mutations in five patients with mitochondrial encephalomyopathy. Biochim Biophys Acta 2009;1787:491-501.
31. Lim BC, Park JD, Hwang H, Kim KJ, Hwang YS, et al. Mutations in ND subunits of complex I are an important genetic cause of childhood mitochondrial encephalopathies. J Child Neurol 2009;24:828-32.
32. Funalot B, Reynier P, Vighetto A, Ranoux D, Bonnefont JP, et al. Leigh-like encephalopathy complicating Leber's hereditary optic neuropathy. Ann Neurol 2002;52:374-7.
33. Tarnopolsky MA, Baker SK, Myint T, Maxner CE, Robitaille J, et al. Clinical variability in maternally inherited leber hereditary optic neuropathy with the G14459A mutation. Am J Med Genet A 2004;124A:372-6.
34. Andreu AL, Bruno C, Dunne TC, Tanji K, Shanske S, et al. A nonsense mutation (G15059A) in the cytochrome b gene in a patient with exercise intolerance and myoglobinuria. Ann Neurol 1999;45:127-30.
35. Mueller EE, Eder W, Ebner S, Schwaiger E, Santic D, et al. The mitochondrial T16189C polymorphism is associated with coronary artery disease in Middle European populations. PLoS One 2011;6:e16455.
36. Gastaldi G, Giacobino JP, Ruiz J. Metabolic syndrome, a mitochondrial disease? Rev Med Suisse 2008;4:1387-8. 1390-1. (in French)
37. Indo HP, Davidson M, Yen HC, Suenaga S, Tomita K, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007;7:106-18.
38. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008;320:661-4.
39. Maassen JA, 'T Hart LM, van Essen E, Heine RJ, Nijpels G, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 2004;53:S103-9.
40. Choksi KB, Boylston WH, Rabek JP, Widger WR, Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport complexes. Biochim Biophys Acta 2004;1688:95-101.
41. Smith SC Jr. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007;120:S3-11.
42. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597-602.
43. Sorriento D, Pascale AV, Finelli R, Carillo AL, Annunziata R, et al. Targeting mitochondria as therapeutic strategy for metabolic disorders. ScientificWorldJournal 2014;2014:604685.
44. Ho SS. Current status of carotid ultrasound in atherosclerosis. Quant Imaging Med Surg 2016;6:285-96.
45. Polak JF, Szklo M, Kronmal RA, Burke GL, Shea S, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013;2:e000087.
47. Sobenin IA, Galitsyna EV, Grechko AV, Orekhov AN. Small dense and desialylated low density lipoprotein in diabetic patients. Vessel Plus 2017;1:29-37.
